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wrong could be debated, but one fact re-
mains: thromboembolic complications
have been an unusual cause of early post-
operative morbidity or mortality in our ex-
perience, as shown by the 0.5% incidence
that we reported in the CPB group. In an
article by Clagett and associates,1 there was
no mention of specific prophylaxis for car-
diac surgery. Nevertheless, we do agree on
the importance of prophylaxis in OPCAB
surgery. So far, we have not found any
negative side effects associated with it.
Since we started applying this policy to all
our OPCAB patients, we have seen an ob-
vious decrease in the incidence of throm-
boembolism without any increased bleed-
ing complications or transfusion needs.
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Single fiber skeletal muscle
transplantation or purified myoblast
engraftment?
To the Editor:
We read with interest the article of Suzuki
and colleagues,1 “Single Fibers of Skeletal
Muscle as a Novel Graft for Cell Trans-
plantation to the Heart.” They investigated
the feasibility of single skeletal muscle fi-
bers as a vehicle to deliver putative myo-
blasts-myotubes into the myocardium in rat
models. They further demonstrated the im-
provement of cardiac function and histo-
logic evidence of cell proliferation and sur-
vival after single muscle fiber engraftment
into the infarcted myocardium.
This is an important study in skeletal
myoblast transplantation for cardiac repair,
because mechanisms for improvement of
cardiac function after myoblast transplan-
tation have not been clearly identified. Al-
though clinical application of myoblast
transplantation for cardiac repair is already
being assessed in phase I human studies,2
many questions regarding the optimization
of the transplantation conditions and pro-
cedure remain unanswered.3
It appears logical to consider that the
number of myoblasts that repopulate the
infarcted myocardium must be important.
In all other experimental studies, a signif-
icantly larger number of cells were im-
planted. Improvement in myocardial func-
tion has been directly related to the number
of cells injected which in rodents is 3 to 6
million cells and large animals as many as
1 billion cells. Suzuki and colleagues1 in
their study used only 4 single fibers per
heart for injection. According to their find-
ings, each single fiber retained 20 myo-
blasts, as assessed by immunostaining for
M-cadherin, meaning that only 80 myo-
blasts were transplanted. Therefore myo-
blasts had to undergo extensive prolifera-
tion after transplantation to achieve an
optimum cell count for beneficial effect. It
seems unreasonable to expect that as few as
4 single skeletal fibers (80 myoblasts)
would bring about significant improvement
of heart function. From the figures shown,
the extent of repopulation of the myocar-
dium with cells is unclear, and only a few
myotubules have been formed, which
would be unlikely to improve cardiac func-
tion significantly in a severely damaged
heart.
The disadvantages pointed out by Su-
zuki and colleagues1 of using expanded
cultures of myoblast as opposed to single
fibers are only theoretic. The problem of
embolism from myoblast injection has
never been reported, even when they are in-
jected intra-arterially or intracoronarily.4,5
Similarly, in clinical perspective, delaying an
elective operation on a patient in stable con-
dition to expand the myoblast number is not
a major problem. Our experience and the
current literature do not indicate that repeated
passaging of myoblasts leads to significant
deterioration or problems.
One of the important findings in this
article is the development of multinucleate
branching myotubes. Because the grafted
myofibers were postmitotic, it was deduced
that skeletal myoblasts were the source of
the newly formed fibers. In a porcine model
of chronic ischemia with transient immu-
nosuppression, we implanted lacZ-positive
human myoblasts of greater than 95% pu-
rity. At 6 weeks we demonstrated similar
formation of new branching centrally lo-
cated multinucleate myotubules. Most of
the nuclei stained positively for -galacto-
sidase (Figure 1). We believe that after
myoblast transplantation neomyogenesis
results in fibers with phenotypic features
similar to skeletal and cardiac muscles and
that this is the mechanism of improvement
in cardiac function.
Eugene K. W. Sim, FRCS
Husnain K. Haider, PhD
Peter K. Law, PhD
National University of Singapore
Singapore
Figure 1. Xenotransplanted human skeletal myoblasts carrying lacZ reporter gene with
nuclear localization signal in porcine heart model of chronic ischemia at 6 weeks after
transplantation. Tissue sections were stained with X-gal according to standard protocol.
Arrows represent donor human myoblast nuclei.
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Reply to the Editor:
We appreciate the interest of Sim and col-
leagues in our article describing the im-
plantation of single, isolated skeletal mus-
cle fibers into the heart. We agree that
many important questions need to be an-
swered before further clinical trials of myo-
blast transplantation into the heart.
A major issue is the mechanism by
which skeletal myoblast transplantation
can improve cardiac function. Sim and
colleagues’ suggestion that the improve-
ment in myocardial function is directly
related to the number of myoblasts im-
planted has not been firmly established.
We consider the quality of cells im-
planted to be as important as, or perhaps
even more important than, cell number.1
In addition, only one recent study with
donor cardiac myocytes has attempted to
adequately quantify graft cell survival
with quantitative real-time polymerase
chain reaction, and no direct correlation
between numbers of surviving donor-de-
rived cells and functional improvement
was made in that study.2
It should be noted that the issues re-
garding the adverse effects of prolonged
in vitro culture on skeletal myoblasts are
far from theoretical, as suggested by Sim
and colleagues. There is clear evidence
for the susceptibility to infection, as well
as altered immunogenicity and adverse
effects on myogenicity.3 With respect to
the risk of coronary embolism after cell
transplantation, we have reported that in-
fusion of more than 2 million myoblasts
in a volume of 1mL into the coronary
circulation of the rat heart results in em-
bolization, with edema and cardiac ar-
rest.4
Sim and colleagues suggest that the
functional benefit of myoblast transplanta-
tion is due, at least in an ischemic heart
failure model, to the formation of new mus-
cle (“neomyogenesis”) with “phenotypic
features similar to skeletal and cardiac
muscle.” This statement is not clear, and
such a mechanism would require extensive
functional, electrophysiological, and mo-
lecular characterization.
The relevance of the discordant hu-
man-to-pig xenogenic model cited by
Sim and colleagues is not clear, and it is
unlikely that a significant degree of myo-
blast survival would be seen after graft-
ing with only transient immunosuppres-
sion—although the protocol for this is
not detailed. We find interpretation of the
staining in the figure difficult. With re-
spect to labeling, the promoter driving
reporter lacZ expression is not stated;
thus one cannot be absolutely certain as
to the identity of the stained cells in the
presented figure. The varied distribution
of the X-gal stain is difficult to explain,
and counterstaining with skeletal myo-
sin–specific antibody, as reported in our
own data, would be informative; an ad-
ditional nuclear marker would confirm
the specificity of the stain.
The key findings in our study are that
myogenic precursor cells derived from the
parent fibers appeared to survive, prolifer-
ate, and differentiate within the cardiac mi-
croenvironment. Further, this treatment im-
proved cardiac function in ischemic and
dilated cardiomyopathy models to a degree
that was far beyond what one might expect
for the amount of new muscle formed. We
have proposed at least two possible causes
for this remarkable effect. One is a para-
crine effect resulting in neoangiogenesis,
as shown in our article; the other is the
endogenous protection afforded to the res-
ident satellite cells by the parent fiber. This
latter effect may be important in enhancing
graft cell survival in the most hazardous
acute phase after grafting and may also
deliver satellite cells that have some impor-
tant qualitative differences. We consider
the skeletal muscle fiber system to be
promising, although further studies are
needed to investigate the effects that we
have proposed.
Bari Murtuza
Ken Suzuki
Magdi H. Yacoub
Harefield Hospital Heart Science Centre
Imperial College Faculty of Medicine
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Large cell neuroendocrine
carcinoma of the lung: What we
have to do
To the Editor:
I read with interest the excellent article of
Takei and colleagues1 about large cell neu-
roendocrine carcinoma (LCNC) of the
lung. This series represents the largest ever
published in English language literature.
The family of neuroendocrine tumors of
the lung has recently been the object of
study by several pathologists and surgeons.
The recent World Health Organization
classification criteria2 consider neuroendo-
crine tumors of the lung as a distinct subset
of neoplasm with specific morphologic, ul-
trastructural, immunohistochemical, and
molecular characteristics. Travis and asso-
ciates3 distinguish between typical and
atypical carcinoid, LCNC, and small cell
neuroendocrine carcinoma of the lung. Of
these tumors, LCNCs appear to have an
intermediate biologic behavior between
atypical carcinoid and small cell carcino-
ma.3 LCNCs have a tendency to spread
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